Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 19Ovarian Neoplasms 17Neuroblastoma 15Fallopian Tube Neoplasms 13Neoplasms 6Carcinoma, Ovarian Epithelial 6Ganglioneuroblastoma 5Brain Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Neoplasm Metastasis 3Lung Neoplasms 3Glioma 3Central Nervous System Neoplasms 3Sarcoma, Ewing 2Rhabdoid Tumor 2Retinoblastoma 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Wilms Tumor 1Thrombocythemia, Essential 1SCLC, Extensive Stage 1SCLC 1Rhabdomyosarcoma 1Retinal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Pediatric Brain Tumor 1

Interventions

Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pleuropulmonary blastoma × Topotecan × 1 year × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡